Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Breast 7CNS 6Sarcoma 4Gynecologic 4Genitourinary 4Gastrointestinal 4Tumor-Agnostic 3Thoracic 2Plasma cell 2Other hematologic neoplasm 2Other 2NET 1Myeloid 1Lymphoid 1Head & Neck 1Endocrine 1Classical hematology 1

Conditions

Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2

Interventions

Carboplatin 1145Cisplatin 874Pemetrexed 832pembrolizumab 604Paclitaxel 597Docetaxel 535Gemcitabine 424Radiotherapy 374Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 294durvalumab 254Drug Therapy 233osimertinib 217atezolizumab 207Radiosurgery 188Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 123Magnetic Resonance Spectroscopy 120Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Quality of Life × Thoracic × Clear all
NCT06646471 2026-04-29

PROMETHEE

Groupe Francais De Pneumo-Cancerologie

Phase 4 Recruiting
500 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03628144 2020-09-10

Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡